Connection

TODD ROSENGART to Vascular Endothelial Growth Factor A

This is a "connection" page, showing publications TODD ROSENGART has written about Vascular Endothelial Growth Factor A.
  1. "Triplet" polycistronic vectors encoding Gata4, Mef2c, and Tbx5 enhances postinfarct ventricular functional improvement compared with singlet vectors. J Thorac Cardiovasc Surg. 2014 Oct; 148(4):1656-1664.e2.
    View in: PubMed
    Score: 0.359
  2. Long-term follow-up assessment of a phase 1 trial of angiogenic gene therapy using direct intramyocardial administration of an adenoviral vector expressing the VEGF121 cDNA for the treatment of diffuse coronary artery disease. Hum Gene Ther. 2013 Feb; 24(2):203-8.
    View in: PubMed
    Score: 0.329
  3. In vivo cardiac cellular reprogramming efficacy is enhanced by angiogenic preconditioning of the infarcted myocardium with vascular endothelial growth factor. J Am Heart Assoc. 2012 Dec; 1(6):e005652.
    View in: PubMed
    Score: 0.329
  4. Double-blinded, placebo-controlled, randomized gene therapy using surgery for vector delivery. Hum Gene Ther. 2012 May; 23(5):438-41.
    View in: PubMed
    Score: 0.314
  5. Angiogenic Gene Therapy for Refractory Angina: Results of the EXACT Phase 2 Trial. Circ Cardiovasc Interv. 2024 05; 17(5):e014054.
    View in: PubMed
    Score: 0.181
  6. Adenoviral-mediated transfer of vascular endothelial growth factor 121 cDNA enhances myocardial perfusion and exercise performance in the nonischemic state. J Thorac Cardiovasc Surg. 2004 Feb; 127(2):535-40.
    View in: PubMed
    Score: 0.178
  7. EXACT Trial: Results of the Phase 1 Dose-Escalation Study. Circ Cardiovasc Interv. 2023 08; 16(8):e012997.
    View in: PubMed
    Score: 0.171
  8. In situ reprogramming to transdifferentiate fibroblasts into cardiomyocytes using adenoviral vectors: Implications for clinical myocardial regeneration. J Thorac Cardiovasc Surg. 2017 02; 153(2):329-339.e3.
    View in: PubMed
    Score: 0.107
  9. Safety of direct cardiac administration of AdVEGF-All6A+, a replication-deficient adenovirus vector cDNA/genomic hybrid expressing all three major isoforms of human vascular endothelial growth factor, to the ischemic myocardium of rats. Hum Gene Ther Clin Dev. 2013 Mar; 24(1):38-46.
    View in: PubMed
    Score: 0.083
  10. Angiogenic pretreatment to enhance myocardial function after cellular cardiomyoplasty with skeletal myoblasts. J Thorac Cardiovasc Surg. 2007 Feb; 133(2):478-484.e2.
    View in: PubMed
    Score: 0.055
  11. Calcified rheumatic valve neoangiogenesis is associated with vascular endothelial growth factor expression and osteoblast-like bone formation. Circulation. 2005 Jun 21; 111(24):3296-301.
    View in: PubMed
    Score: 0.049
  12. Homozygous deletion of early growth response 1 gene and critical limb ischemia after vascular ligation in mice: evidence for a central role in vascular homeostasis. J Thorac Cardiovasc Surg. 2004 Oct; 128(4):595-601.
    View in: PubMed
    Score: 0.047
  13. Angiogenic pretreatment improves the efficacy of cellular cardiomyoplasty performed with fetal cardiomyocyte implantation. J Thorac Cardiovasc Surg. 2004 Apr; 127(4):1041-9; discussion 1049-51.
    View in: PubMed
    Score: 0.045
  14. Therapeutic angiogenesis: a biologic bypass. Cardiology. 2004; 101(1-3):131-43.
    View in: PubMed
    Score: 0.044
  15. Gene therapy with adenovirus-mediated myocardial transfer of vascular endothelial growth factor 121 improves cardiac performance in a pacing model of congestive heart failure. J Thorac Cardiovasc Surg. 2002 Jun; 123(6):1101-13.
    View in: PubMed
    Score: 0.040
  16. Gene therapy for coronary artery disease. Adv Card Surg. 2001; 13:107-20.
    View in: PubMed
    Score: 0.036
  17. Clinical trials in coronary angiogenesis: issues, problems, consensus: An expert panel summary. Circulation. 2000 Sep 12; 102(11):E73-86.
    View in: PubMed
    Score: 0.035
  18. Focal angiogen therapy using intramyocardial delivery of an adenovirus vector coding for vascular endothelial growth factor 121. Ann Thorac Surg. 2000 Jan; 69(1):14-23; discussion 23-4.
    View in: PubMed
    Score: 0.033
  19. Six-month assessment of a phase I trial of angiogenic gene therapy for the treatment of coronary artery disease using direct intramyocardial administration of an adenovirus vector expressing the VEGF121 cDNA. Ann Surg. 1999 Oct; 230(4):466-70; discussion 470-2.
    View in: PubMed
    Score: 0.033
  20. Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation. 1999 Aug 03; 100(5):468-74.
    View in: PubMed
    Score: 0.033
  21. The role of phosphatidylinositol 3-kinase in vascular endothelial growth factor signaling. J Biol Chem. 1999 Apr 09; 274(15):10002-7.
    View in: PubMed
    Score: 0.032
  22. Transmyocardial laser revascularization and angiogenesis: the potential for therapeutic benefit. Semin Thorac Cardiovasc Surg. 1999 Jan; 11(1):29-35.
    View in: PubMed
    Score: 0.031
  23. Salvage angiogenesis induced by adenovirus-mediated gene transfer of vascular endothelial growth factor protects against ischemic vascular occlusion. J Vasc Surg. 1998 Apr; 27(4):699-709.
    View in: PubMed
    Score: 0.030
  24. Biologic bypass with the use of adenovirus-mediated gene transfer of the complementary deoxyribonucleic acid for vascular endothelial growth factor 121 improves myocardial perfusion and function in the ischemic porcine heart. J Thorac Cardiovasc Surg. 1998 Jan; 115(1):168-76; discussion 176-7.
    View in: PubMed
    Score: 0.029
  25. Vascular endothelial growth factor is the major angiogenic factor in omentum: mechanism of the omentum-mediated angiogenesis. J Surg Res. 1997 Feb 01; 67(2):147-54.
    View in: PubMed
    Score: 0.027
  26. Direct in vivo gene transfer to canine myocardium using a replication-deficient adenovirus vector. Ann Thorac Surg. 1996 Aug; 62(2):425-33; discussion 433-4.
    View in: PubMed
    Score: 0.026
  27. Systemic interleukin-6 responses following administration of adenovirus gene transfer vectors to humans by different routes. Mol Ther. 2002 Aug; 6(2):287-97.
    View in: PubMed
    Score: 0.010
  28. Safety of local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of morbid conditions. Hum Gene Ther. 2002 Jan 01; 13(1):15-63.
    View in: PubMed
    Score: 0.010
  29. Analysis of risk factors for local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of comorbid conditions. Hum Gene Ther. 2002 Jan 01; 13(1):65-100.
    View in: PubMed
    Score: 0.010
  30. Use of quantitative TaqMan real-time PCR to track the time-dependent distribution of gene transfer vectors in vivo. Mol Ther. 2000 Dec; 2(6):649-56.
    View in: PubMed
    Score: 0.009
  31. Variability of human systemic humoral immune responses to adenovirus gene transfer vectors administered to different organs. J Virol. 1999 Aug; 73(8):6729-42.
    View in: PubMed
    Score: 0.008
  32. Safety of direct myocardial administration of an adenovirus vector encoding vascular endothelial growth factor 121. Hum Gene Ther. 1999 May 20; 10(8):1331-48.
    View in: PubMed
    Score: 0.008
  33. Regional angiogenesis induced in nonischemic tissue by an adenoviral vector expressing vascular endothelial growth factor. Hum Gene Ther. 1997 Jan 20; 8(2):215-27.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.